TRDA (Entrada Therapeutics) ROCE %: -50.57% (As of Mar. 2026)

What is Entrada Therapeutics ROCE %?

Entrada Therapeutics TRDA +1.68% 23 ROCE % is -50.57% as of Mar. 2026. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Entrada Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -50.57%.

Entrada Therapeutics (NAS:TRDA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Entrada Therapeutics ROCE % Related Terms

Entrada Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics ROCE % Chart

Entrada Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-30.14

-36.75

-1.17

11.79

-37.61

Entrada Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-18.26	-41.78	-46.02	-45.52	-50.57

23GF Score

Entrada Therapeutics Inc TRDA

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Entrada Therapeutics ROCE % Calculation

Entrada Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-157.898	/	( ( (526.321 - 39.482)	+	(377.378 - 24.451) )	/ 2 )
	=	-157.898	/	( (486.839	+	352.927)	/ 2 )
	=	-157.898	/	419.883
	=	-37.61 %

Entrada Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-169.212	/	( ( (377.378 - 24.451)	+	(335.518 - 19.195) )	/ 2 )
	=	-169.212	/	( ( 352.927	+	316.323 )	/ 2 )
	=	-169.212	/	334.625
	=	-50.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -50.57% mean?

Entrada Therapeutics (TRDA) has a ROCE % of -50.57% as of Mar. 2026.

Is Entrada Therapeutics' ROCE % too high?

Entrada Therapeutics' current ROCE % is -50.57%. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Entrada Therapeutics' ROCE % compare to SABS and ACIU?

Entrada Therapeutics' ROCE % of -50.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Entrada Therapeutics's current ROCE % is -50.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Entrada Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.26 — trading 689.1% above its estimated fair value. The current ROCE % is -50.57%. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current ROCE % is -50.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.26 is trading 689.1% above its estimated GF Value™ of $0.92. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

ROCE %: -50.57%
GF Value™: $0.92 vs. price of $7.26 (689.1% above fair value)
GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SABS ACIU AVXL MGNX ZNTL CNTX TARA HUMA NVCT ALXO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210

Website https://www.entradatx.com

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

23GF Score

Get the complete analysis for TRDA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26

Price

$0.92

GF Value

View TRDA Analysis

See ROCE % data for all stocks →